Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
What hotspot and heterogeneity metrics do you utilize when delivering PMRT to a patient who has had breast reconstruction?
How do you use 105%, 107% and max dose metrics differently compared with non-reconstructed cases?
Answer from: Radiation Oncologist at Community Practice
I try to follow the same as intact breast. Limiting hot spot < 110 and V 105 < 5-10% and not hot spot in IM fold. Patel et al., PMID 30145393
Sign In
or
Register
to read more
22655
Related Questions
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
Do you omit PMRT for patients who would have been eligible for NSABP B-51, but are found to have significant pure LVSI only, without stromal carcinoma, after neoadjuvant chemotherapy?
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
How, if at all, does your practice differ between male and female breast cancer patients with respect to the use of bolus?
When treating chestwall + RNI with VMAT, how much do you crop the PTV into lung as is done with the PTVeval in 3D contouring guides?
What are your top takeaways in Breast Cancer from ESMO 2025?
What volumes and dose would you use for a chest wall recurrence in a patient who had previous mastectomy and completed only a partial prior course of PMRT?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?